The European Patent Office ruled in Sanofi and Regeneron’s favor, invalidating certain claims of Amgen’s European patent directed to antibodies relevant to Praluent.
- Praluent will continue to be available in European countries where it is approved for use and for sale, Sanofi said
- Sanofi has sole rights for Praluent outside the U.S., and Regeneron has sole rights in the U.S.
- NOTE:
May 8 , Amgen: Japan Supreme Court Rejects Sanofi Appeal on PCSK9 Patent - NOTE:
Aug. 2019 , Amgen Patents on Repatha Cholesterol Drug Are Ruled Invalid
To view the source of this information click
To contact the reporter ...